52bfcfee-5de0-4e8f-9f11-7a643858bcb0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.510
- INTERFERON_ALPHA_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- ALLOGRAFT_REJECTION+0.410
- OXIDATIVE_PHOSPHORYLATION+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
- COMPLEMENT+0.310
- INFLAMMATORY_RESPONSE+0.240
- UV_RESPONSE_DN+0.230
Top 10 suppressed
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.290
- MITOTIC_SPINDLE-0.240
- PI3K_AKT_MTOR_SIGNALING-0.230
- DNA_REPAIR-0.220
- CHOLESTEROL_HOMEOSTASIS-0.210
- P53_PATHWAY-0.190
- MYC_TARGETS_V1-0.180
- GLYCOLYSIS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0EB-01A-11R-A034-07 | — | B | 0.829 |
| 2 | MDT-AP-2181 | Med | Medulloblastoma | 0.804 |
| 3 | TCGA-05-4430-01A-02R-1206-07 | — | cohortA1 | 0.801 |
| 4 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.781 |
| 5 | TCGA-A8-A07J-01A-11R-A00Z-07 | — | A | 0.780 |
| 6 | C3N-02090 | — | cohortSQ1 | 0.780 |
| 7 | TCGA-46-3766-01A-01R-0980-07 | — | cohortSQ1 | 0.779 |
| 8 | TCGA-CN-6017-01A-11R-1686-07 | — | — | 0.779 |
| 9 | TCGA-E2-A1L9-01A-11R-A13Q-07 | — | A | 0.772 |
| 10 | TCGA-OR-A5L5-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |